EMA issues advice on use of sotrovimab (VIR-7831) for treating COVID-19 | EMA

Einde Vaccinatie-dwang c.q. -drang

EMA’s human medicines committee (CHMP) has completed its review on the use of the monoclonal antibody sotrovimab (also known as VIR-7831 and GSK4182136) to treat patients with COVID-19. This review was undertaken to provide a harmonised scientific opinion at EU level to support national decision-making on the possible use of the antibody prior to marketing authorisation.The Agency concluded that sotrovimab can be used to treat confirmed COVID-19 in adults and adolescents (aged 12 years and above and weighing at least 40 kg) who do not require supplemental oxygen therapy and who are at risk of progressing to severe COVID-19.

EMA issues advice on use of sotrovimab (VIR-7831) for treating COVID-19 | European Medicines Agency